•  
  •  
  •  
  •  

2026-05-24 05:37:37

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Prithvi Exchange India Ltd announces financial performance for the 4th quarter ended March 31, 2026
  • SMS Pharmaceuticals Reports Robust FY26 Performance: PAT Soars 48% and EBITDA Margins Expand to 19%
  • NBCC India Ltd secures 2 orders worth Rs. 42.55 crores
  • Icon Facilitators Limited receives order worth Rs. 2.69 crore
  • Fabtech Technologies Cleanrooms Ltd receives order worth Rs. 65.10 crores

Keywords Selected:  LifeSciences

IPO News

  • Shilpa Pharma Lifesciences Ltd to file for IPO

Stock Report

  • Eris delivers 11% yoy growth in Domestic Formulations with 37% EBIDTA margin in FY26
  • Zydus Lifesciences Limited Financial Performance for Q4 & Full Year FY26
  • Suven Life Sciences Reaches 76% Enrollment milestone in Global Phase 3 Masupirdine (SUVN-502) Trial for Agitation in Alzheimer's Dementia
  • Cohance Lifesciences Ltd Q4 FY2025-26 consolidated PAT slides to Rs. 19.55 crores
  • Sai Life Sciences becomes first Indian CRDMO with a site powered by 100% renewable energy
  • Persistent Achieves Databricks Brickbuilder Specialization for Healthcare & Life Sciences, Expanding Production-Ready Data and AI Solutions For Regulated Environments
  • USFDA inspection concludes at Zydus' Biologics Injectable plant, Ahmedabad
  • RPG Life Sciences Ltd Q4 FY2025-26 consolidated profit at Rs. 29.90 crores
  • RPG Life Sciences Limited recommends dividend of Rs. 24
  • ASMS and Huwel to Launch Cubo, India's Revolutionary Point-ofCare Molecular Diagnostics Platform Built for the World
  • Astec LifeSciences Ltd Q4 FY2026 consolidated loss at Rs. 7.75 crores
  • Huwel Lifesciences & ASMS Onboard Singapore-Based Partner to Accelerate Southeast Asia Expansion
  • Umang Vohra to lead Cohance Lifesciences as Executive Chairman & Group CEO
  • Zydus receives approval from DCGI to initiate Phase III trials of Zintrodiazine, a novel anti-malarial candidate
  • USFDA Inspection at Innoxel Lifesciences Private Limited
  • Zydus receives EIR for oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Rubicon Research enters the Indian CNS formulations market with the acquisition of Arinna Lifesciences Ltd
  • Zydus receives final approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg
  • Granules Life Sciences Receives VAI Classification following US FDA Inspection
  • Zydus launches Semaglutide Injection in an innovative, reusable multi-dose pen device in India
  • Eris Lifesciences Ltd to launch Weekly Shot of Semaglutide Starting at ₹220 Per Shot
  • Zydus launches Aerolife Mini™, to simplify inhaler use for asthma and COPD patients
  • Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India
  • Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India

Latest Post

  • Prithvi Exchange India Ltd announces financial performance for the 4th quarter ended March 31, 2026
  • SMS Pharmaceuticals Reports Robust FY26 Performance: PAT Soars 48% and EBITDA Margins Expand to 19%
  • NBCC India Ltd secures 2 orders worth Rs. 42.55 crores
  • Icon Facilitators Limited receives order worth Rs. 2.69 crore
  • Fabtech Technologies Cleanrooms Ltd receives order worth Rs. 65.10 crores


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025